|
| Author | Nonhaematopoietic EPO derivative | Model | Inference |
|
| Erbayraktar et al. 2003 [10] | Asialo EPO | In vivo model of cerebral and spinal cord ischaemia plus sciatic nerve injury | Neuroprotection-recovery of paraplegia |
| Leis et al. 2004 [11] | Carbamylated EPO (CEPO) | In vitro and in vivo models of neural injury | Demonstration of tissue protective properties of CEPO in neural tissue |
| Fiordaliso et al. 2005 [12] | CEPO | In vivo model of rat myocardial infarction | Reduction in the size of myocardial infarct |
| Fantacci et al. 2006 [13] | CEPO | In vivo model of metabolic stress in mice induced by chronic hypoxia (CH) | CEPO reduced metabolic stress caused by CH and improved cellular survival independent of haematopoiesis. |
| Erbayraktar et al. 2006 [14] | CEPO | In vivo model of radiosurgically induced brain injury in rats | Decreased necrosis of the brain tissue |
| Erbayraktar et al. 2009 [15] | CEPO and ARA 290 | In vivo models of decubitus ulcers and peritonitis | Improved healing and less intraperitoneal adhesion formation |
| Ahmet et al. 2010 [16] | ARA 290 | In vivo model of myocardial ischemia | Reduction in the size of infarct and improvement of ejection fraction |
| Joshi et al. 2010 [17] | ARA 290 | In vitro | Decreased apoptosis of myotubes but no effect on angiogenesis |
| Joshi et al. 2011 [18] | ARA 290 | In vitro | Decreased ischaemia-induced inflammation and apoptosis of myotubes |
|
